Format

Send to

Choose Destination
Clin Drug Investig. 2018 May;38(5):475-476. doi: 10.1007/s40261-018-0623-7.

Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option.

Author information

1
Hematology Division, IRCCS Ca' Granda-Maggiore Policlinico Hospital Foundation, University of Milan, Via Francesco Sforza 35, 20122, Milan, Italy. alessandra.iurlo@policlinico.mi.it.
2
Hematology Division, IRCCS Ca' Granda-Maggiore Policlinico Hospital Foundation, University of Milan, Via Francesco Sforza 35, 20122, Milan, Italy.
3
Department of Cellular Biotechnologies and Hematology, University "La Sapienza" of Rome, Rome, Italy.
PMID:
29363026
DOI:
10.1007/s40261-018-0623-7

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center